Robin Shah: Communicating With Patients About the Value of Biosimilars

Robin Shah, chief commercial officer of OneOncology, addresses how practices can communicate the value of biosimilars to patients.


So the way that we think about communicating with patients in general about this whole cost of care is being transparent through the initial consult process. So in all of our clinics, we have financial counselors that work with all of our practices and patients so they truly understand what treatment they're getting, then what the cost of that care is. And with biosimilars being introduced, we can now show and represent that the patients are getting the same outcomes, with the lower cost of care, with the agents that are available.